Extraordinary General Meeting of Shareholders to Approve Business Combination Scheduled for May 27, 2026BOSTON and NEW YORK, ...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the pricing of its initial public offering of 24,000,000 units, upsized from 20,000,000 units, at a price of ...

So, the natural question for Cartesian Therapeutics (NASDAQ:RNAC) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual ...

Bounteous, an AI services firm, today announced its acquisition of Cartesian, a specialist consulting firm focused on the ...

View Cartesian Growth Corp. III Class A CGCT stock quote prices, financial information, real-time forecasts, and company news from CNN.

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement ...

Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate ...

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in ...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized ...